ImageneBio, Inc. (IMA) stock
IMANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$3.45−0.27 (-7.26%)
Close on Nov 12, 2026Market cap $39.16MP/E –Yield –
ImageneBio profit margin
Profit margin (net margin) is net income as a percentage of revenue.
ImageneBio's profit margin for the twelve months ending Dec 31, 2025 was -5668.6%. For fiscal 2025 it was -5668.6%, against -1044.8% the year before. The highest annual figure on record is -110.1% in fiscal 2021.
Annual profit margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -5668.6% | −4623.8 |
| FY2024 | Dec 31, 2024 | -1044.8% | −300.6 |
| FY2023 | Dec 31, 2023 | -744.2% | −303.9 |
| FY2022 | Dec 31, 2022 | -440.3% | −330.2 |
| FY2021 | Dec 31, 2021 | -110.1% | +371.3 |
| FY2020 | Dec 31, 2020 | -481.4% | – |
Quarterly profit margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q1 FY2025 | Mar 31, 2025 | -759.6% | +94.4 |
| Q3 FY2024 | Sep 30, 2024 | -90.9% | +176.7 |
| Q4 FY2023 | Dec 31, 2023 | -2957.4% | −2698.7 |
| Q3 FY2023 | Sep 30, 2023 | -1463.5% | −1192.7 |
| Q2 FY2023 | Jun 30, 2023 | -854.0% | +4510.1 |
| Q1 FY2023 | Mar 31, 2023 | -267.6% | +230.0 |
| Q4 FY2022 | Dec 31, 2022 | -258.7% | −272.5 |
| Q3 FY2022 | Sep 30, 2022 | -270.8% | +116.7 |
| Q2 FY2022 | Jun 30, 2022 | -5364.1% | −5006.8 |
| Q1 FY2022 | Mar 31, 2022 | -497.6% | −217.9 |
| Q4 FY2021 | Dec 31, 2021 | 13.8% | +40092.3 |
| Q3 FY2021 | Sep 30, 2021 | -387.5% | −167.5 |
| Q2 FY2021 | Jun 30, 2021 | -357.3% | −193.4 |
| Q1 FY2021 | Mar 31, 2021 | -279.7% | −64.5 |
| Q4 FY2020 | Dec 31, 2020 | -40078.5% | – |
| Q3 FY2020 | Sep 30, 2020 | -219.9% | – |
| Q2 FY2020 | Jun 30, 2020 | -163.9% | – |
| Q1 FY2020 | Mar 31, 2020 | -215.2% | – |
See a number that looks wrong?